RecoveryResearch Phase

Thymosin Beta-4 Fragment (TB4-Frag)

Overview

Thymosin Beta-4 Fragment refers to bioactive segments derived from the 43-amino acid thymosin beta-4 protein, most commonly a 7-amino acid N-terminal sequence (Ac-SDKP). These fragments retain specific biological activities of the parent peptide, including modulation of actin polymerization, angiogenesis, and inflammation. Shorter fragments may offer improved stability and targeted activity compared to full-length thymosin beta-4.

Key Research Findings

The tetrapeptide Ac-SDKP has been studied in rodent models of fibrosis and hypertension, demonstrating anti-inflammatory and antifibrotic effects. Preclinical wound healing models have shown enhanced angiogenesis and epithelialization with various TB4 fragments. Clinical evidence in humans remains limited to small exploratory studies without large-scale controlled trials.

Route of Administration

Subcutaneous injection, Topical

Regulatory Status

Research Phase

Interested in Thymosin Beta-4 Fragment (TB4-Frag)?

Find a verified provider experienced with Thymosin Beta-4 Fragment (TB4-Frag) protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Thymosin Beta-4 Fragment (TB4-Frag) Provider

Related Peptides

BPC-157

Research Phase

A synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis and the expression of growth factors including VEGF, EGF, and NO-mediated pathways. It has demonstrated cytoprotective and wound-healing properties across multiple tissue types in preclinical models, including tendon, muscle, ligament, and gastrointestinal mucosa.

TB-500 (Thymosin Beta-4)

In Clinical Trials

Thymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue repair. It promotes wound healing by upregulating cell-building proteins such as actin and laminin, facilitating cell migration to sites of injury. TB-500 also has anti-inflammatory properties mediated through NF-kB pathway modulation.

GHK-Cu

Research Phase

A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. GHK-Cu activates tissue remodeling by stimulating collagen synthesis, glycosaminoglycan production, and angiogenesis while suppressing fibrinogen synthesis. It modulates the activity of matrix metalloproteinases and influences over 4,000 genes related to tissue repair.

DSIP (Delta Sleep-Inducing Peptide)

Research Phase

A naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers. It also exhibits stress-protective, analgesic, and neuromodulatory properties.